글로벌 다낭성 난소 증후군(PCOS) 치료 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

다낭성 난소 증후군(PCOS) 치료 시장 분석

다낭성 난소 증후군의 유병률 증가는 다낭성 난소 증후군(PCOS) 치료 시장이 극적으로 성장하는 데 도움이 될 것입니다. 다낭성 난소 증후군의 증가로 효과적인 치료 절차와 약물에 대한 수요가 증가하여 시장에 긍정적인 혜택을 줄 것입니다. 질병 통제 예방 센터에 따르면 생식 연령의 여성 약 500만 명이 다낭성 난소 증후군을 앓고 있습니다. 따라서 사례의 급증은 예측 기간 동안 시장이 수익성 있게 성장할 수 있는 기회를 직접 제공할 것입니다.

다낭성 난소 증후군(PCOS) 치료 시장 규모

전 세계 다낭성 난소 증후군(PCOS) 치료 시장 규모는 2023년에 61억 6천만 달러로 평가되었으며, 2031년까지 98억 1천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 6.00%입니다.

보고 범위 및 시장 세분화       

다낭성 난소 증후군(PCOS) 치료 시장 정의

The polycystic ovarian syndrome (PCOS), is a hormonal condition that affects many women of childbearing age. Polycystic Ovary Syndrome (PCOS) is characterized by irregular or extended menstrual cycles and elevated amounts of male hormones. Although there is currently no cure for PCOS, numerous drugs are used to regulate the menstrual cycle and manage the symptoms of the condition.  It is also caused due to high levels of androgens, low-grade inflammation, cysts in the ovaries, excess insulin and genetic disorders.

Polycystic Ovarian Syndrome (PCOS) Treatment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:

Drivers

• Growing Burden Of Polycystic Ovarian Syndrome (PCOS)

The surging cases of polycystic ovarian syndrome (PCOS), across the world is the most significant factor driving the growth for this market. Additionally, the other factors, including rising prevalence of diabetes and obesity among women, increasing hormonal disorders in women, socioeconomic factors, change in sedentary lifestyle, and growing consumption of unhealthy diet, are also expected to accelerate the market's overall growth.

Furthermore, the expanding healthcare sector, adoption of combination drugs, and rising patient adoption are also expected to fuel market growth. Moreover, the rising awareness among the patients and doctors regarding the chronic diseases and hospital-acquired infections also cushions the market’s growth within the forecasted period. The focus of leading manufacturers on expanding their geographic presence is also projected to bolster the market's growth.

Opportunities

• Growing Investments and Advancements

Moreover, the technological advancements for detection of polycystic ovary syndrome and the growth in awareness about polycystic ovarian syndrome treatment are estimated to generate lucrative opportunities for the market. The untapped potential offered by developing economies combined with rise in adoption of polycystic ovarian syndrome treatment products will further offer numerous growth opportunities for the market.

Restraints/Challenges 

• Side Effects Associated With Drugs

The drugs for treating polycystic ovary syndrome also have various side effects. The side effects associated with drugs such as cardiovascular risks, weight gain, abnormal glucose tolerance, increase insulin resistance and thromboembolic events are expected to obstruct market growth.

• Stringent Drug Approval Policies

Also, the lack of approved therapeutics and lack of FDA drug approval is projected to challenge the polycystic ovarian syndrome (PCOS) treatment market in the forecast period of 2024-2031.

Furthermore, the lack of specific treatment for this disorder along with the unknown etiology and pathophysiology of polycystic ovarian syndrome will also hamper overall growth for the market.

This polycystic ovarian syndrome (PCOS) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the polycystic ovarian syndrome (PCOS) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post Covid-19 Impact on Polycystic Ovarian Syndrome (PCOS) Treatment Market

Healthcare industry was largely impacted by the outbreak of COVID-19. The polycystic ovarian syndrome (PCOS) treatment market does not stand back as it was also adversely affected by it as pandemic had repercussions for many surgical operations, including laparoscopic ovarian drilling The imposition of the lockdown and social distancing restrictions by the government to curb the COVID-19 pandemic outbreak, led to halt of various operations, supply chain disruptions, stifling business growth, suspensions of new developments and has affected the overall treatment procedure which have impacted the market negatively. The non-essential treatment surgeries or procedures were also suspended. According to Experts at the University of Birmingham, patients who have contracted coronavirus and undertake surgery are at an increased risk of postoperative mortality, and that all non-emergent surgeries should be avoided. However, to maintain normal surgical practices, regulatory authorities established a few guidelines unique to each profession that surgeons must implement and follow to continue to offer safe and effective care to their patients throughout the COVID-19 pandemic.

On the brighter side, with the decrease in COVID-19 patients, the restrictions of the government measures are likely to relax. This will help the market witness a slight increment post COVID-19, as normal surgical practices can occur according to few guidelines that surgeons must implement and follow to continue to offer safe and effective care to their patients throughout. Healthcare practitioners have been able to restart their surgery practices as a result of the new standards. As a result, it is envisaged that laparoscopic ovarian drilling treatments will resume their usual growth post- COVID.

Polycystic Ovarian Syndrome (PCOS) Treatment Market Scope

The polycystic ovarian syndrome (PCOS) treatment market is segmented on the basis of drugs, surgery and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Oral Contraceptives
• Antiandrogen
• Insulin-Sensitizing Agents
• Antidepressants
• Anti-Obesity

Surgery

• Wedge Resection
• Laparoscopic Drilling

End User

• Hospital
• Ambulatory Surgical Centers
• Others

Polycystic Ovarian Syndrome (PCOS) Treatment Market Regional Analysis

The polycystic ovarian syndrome (PCOS) treatment market is analyzed and market size insights and trends are provided by country, drugs, surgery and end user as referenced above.

The countries covered in the polycystic ovarian syndrome (PCOS) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the polycystic ovarian syndrome (PCOS) treatment market because of the high awareness and the availability of advanced healthcare facilities within the region.

Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to the government initiatives to raise awareness about the symptoms and diagnosis of PCOS and available treatment, which are increasing the number of women diagnosed with this syndrome within the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Polycystic Ovarian Syndrome (PCOS) Treatment Market Share

다낭성 난소 증후군(PCOS) 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 포함됩니다. 위에 제공된 데이터 포인트는 다낭성 난소 증후군(PCOS) 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 다낭성 난소 증후군(PCOS) 치료 시장 리더는 다음과 같습니다.

• Bayer AG(독일)
• 알러간(아일랜드)
• 머크앤코(미국)
• 파이저 주식회사(미국)
• 암젠(미국)
• 애자일 테라퓨틱스(미국)
• 페링 BV(미국)
• Addex Therapeutics(스위스)
• 마일런 NV(미국)
• 루팡(인도)
• Blairex Laboratories Inc (미국)
• Apothecus Pharmaceutical Corp(미국)
• 엘리 릴리 앤드 컴퍼니(미국)
• 노바티스 AG(스위스)
• BIOCAD Global(러시아)
• Teva Pharmaceutical Industries Ltd(이스라엘)
• 존슨앤존슨 서비스 주식회사(미국)

다낭성 난소 증후군(PCOS) 치료 시장의 최신 동향

• 2020년 1월, Abbvie는 다낭성 난소 증후군 여성에서 안전성과 효능을 테스트하는 화학 물질 Elagolix로 임상 시험을 진행했습니다. 이 회사는 현재 다낭성 난소 증후군(PCOS) 여성에서 Elagolix의 안전성과 효능을 평가하기 위한 2상 다기관, 이중 맹검, 무작위, 위약 대조 연구를 진행하고 있습니다.
• 2020년 1월, Evotec SE와 Bayer AG는 Celmatix Inc.와 함께 다낭성 난소 증후군 치료를 위한 다양한 임상 후보물질을 개발하기 위한 새로운 5년 다중 표적 협력을 시작했으며, 이는 예측 기간 동안 시장을 주도할 것으로 예상됩니다.

SKU-25337